DDInter898 DDInter1139
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Flurbiprofen {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Oxybenzone
Oxybenzone {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Capsicum {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) resembles {v} (Compound) Mefenamic acid
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketoprofen and Ketoprofen (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac and Nepafenac (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketoprofen and Ketoprofen (Compound) resembles Oxybenzone (Compound) and Oxybenzone (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac and Nepafenac (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Mefenamic acid (Compound)
Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) resembles Mefenamic acid (Compound)